48% Vials and 67% Plastic Products, with EVA and Polypropylene Leading Fabrication Materials
The global cell therapy packaging market is estimated to grow from USD 361 million in 2024 to USD 1225 million, growing at a compounded annual growth rate (CAGR) of 11.8% during the forecast period 2024-2035.
Cell therapy is the type of therapy in which the patient’s own cells (autologous), or those from a healthy donor (allogeneic), can be genetically re-programmed to combat various diseases. In cell therapy, patients are injected with viable cells that are deemed to be capable of providing therapeutic benefit. It is important to highlight that cell and gene therapies have been used to treat an array of rare and genetic medical conditions, such as cancer, arthritis, dementia, leukemia and many more which are otherwise hard-to-treat. Currently, more than 30 cell and gene therapies have received FDA approvals, while several therapeutic candidates are in the clinical stages of development. In the past few years, cell therapy has garnered considerable attention from the players engaged in healthcare industry. This can be attributed to the vast potential of cellular therapies in the treatment of rare disorders and sufficient body of evidence validating the clinical benefits and therapeutic potential of this complex class of biologic drug.
The ultimate success of cell therapies is dependent on the safe and timely delivery of viable doses of therapeutic cells to the right patient. Further, in order to ensure the stability and integrity of cell therapy drug products, it is important to maintain specific temperature conditions (depending on the therapy) across the supply chain. These cell therapies also go through several stringent regulatory guidelines at every step of manufacturing in order to ensure the quality standards of the packaging product. Owing to these complexities in the cell therapy packaging domain, several drug developers are moving towards CROs in order to outsource their needs for packaging these drugs. Further, driven by the growing demand for cell-based therapeutics, the market for cell therapy packaging services is anticipated to witness substantial growth during the forecast period.
Cell Therapy Packaging Market Share Insights
The cell therapy packaging report presents an in-depth analysis of the various firms / organizations in cell therapy packaging domain, across different segments, as defined below:
- Base Year: 2023
- Forecast Period: 2024-2035
- Market Size 2024: $361 million
- Market Size 2035: $1.22 billion
- CAGR: 11.8%
- Type of Therapy Packed
- T-cell Therapies
- Dendritic Cell Vaccines
- Stem Cell Therapies
- NK-cell Therapies
- Other Advanced Therapy Medicinal Products
- Scale of Operations
- Clinical Scale
- Commercial Scale
- Package Engineering Design
- Primary Packaging
- Secondary Packaging
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Key Companies Profiled
- Almac
- Catalent Biologics
- Cryoport Systems
- Saint-Gobain
- Thermo Fisher Scientific
- West Pharmaceuticals
- Yourway
- Customization Scope: 15% Free Customization (equivalent to 5 analysts working days)
- PowerPoint Presentation (Complimentary)
- Excel Data Packs (Complimentary)
- Cell Therapy Packaging Service Providers: Market Landscape
- Cell Therapy Packaging Product Providers: Market Landscape
- Company Competitiveness Analysis
- Partnerships and Collaborations Analysis
- Likely Partner Analysis
- Market Forecast and Opportunity Analysis
Cell Therapy Packaging Market Segmentation Overview
Market Share by Type of Therapy Packed
The global cell therapy packaging market is segmented into T-cell therapies, dendritic cell vaccines, stem cell therapies, NK-cell therapies, and other advanced therapy medicinal products, based on the packaging services for different types of therapies. The packing services for T-cell therapies occupies the majority cell therapy packaging market share in 2024 and is expected to remain dominant during the forecast period. This can be attributed to the high adoption of this class of immunotherapy owing to the multitude of benefits, including the ability to treat cancer effectively with decreased chances of relapse.
Market Share by Scale of Operations
This segment highlights the distribution of the cell therapy packaging services across different scales of operation, such as clinical and commercial scale. It is worth highlighting that the clinical scale market is likely to grow at a higher CAGR in the coming years as compared to commercial market owing to the increase in the number of clinical trials in cell therapy industry.
Market Share by Package Engineering Design
Based on the package engineering designs, the cell therapy packaging market is segmented into primary and secondary packaging. Owing to the numerous advantages of primary packaging (cost-effectiveness, protection, dosage control and ease of use), contract manufacturers are investing in the development of primary packaging solutions. The primary packaging market holds the largest market share in 2024 and is expected to remain dominant during the forecast period.
Market Share by Geography
This segment highlights the distribution of the cell therapy packaging across various geographies, such as North America, Europe, Asia-Pacific and rest of the world. According to the projections, Asia-Pacific captures the major share (41%) in cell therapy packaging market and this trend is unlikely to change in the future. It is further worth highlighting that the cell therapy packaging in Europe is expected to grow at a relatively healthy CAGR (13.1%), during the forecast period, 2024-2035.
Cell Therapy Packaging Market Key Insights
The report features an extensive study of the current market landscape, market size and future opportunities associated with cell therapy packaging, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the market report are briefly discussed below.
Competitive Landscape of Cell Therapy Packaging Market (Service Providers)
The cell therapy packaging market landscape is concentrated with the presence of over 30 cell therapy packaging service providers (very large, large, mid-sized and small companies). Of these, 35% of the companies were established post-2001, indicating the presence of several well-established players in the market for cell therapy packaging services. Examples of companies (established in post-2010, in alphabetical order) include A4P (2011), Biotech & Pharma Logistics (2011) and Single Use Support (2016).
Pipeline Analysis: Current Market Landscape of Cell Therapy Packaging Products
The cell therapy packaging market landscape is concentrated with the presence of over 60 cell therapy packaging products. Of these, 48% of the products are vials, followed by shipping containers (28%). Further, it is worth highlighting that 67% of the products use plastic as the fabrication material. In addition, majority of the plastic containers are made of ethylene vinyl acetate and polypropylene. Notable examples of cell therapy bags having ethylene vinyl acetate (EVA plastic) as a fabrication material include (in alphabetical order) EVA Bags (Macopharma), EVA BAGS - BIOCELL (Technoflex) and SAFE2 STEMCHOICE Freezing Bags (Advatis).
Market Trend Analysis: Partnerships and Collaborations have Fueled the Cell Therapy Packaging Market Growth
Several partnerships have been established by industry stakeholders, in order to consolidate their presence in this field, and enhance their capabilities and service portfolio to meet the growing demand for cell therapy packaging products and services. Interestingly, most of the agreements signed between the stakeholders were technology / platform integration and mergers / acquisitions. Further, a wide range of partnership deals were signed with the purpose of cell therapy logistics. For instance, in November 2023, Cryoport and NIPPON EXPRESS signed an agreement to strengthen its CDMO expertise in the domain for temperature-controlled supply chain services.
Market Analysis: Global Cell Therapy Packaging Market Size
The global cell therapy packaging market is estimated to be worth USD 361 million in 2024. Driven by the increasing need for novel cell therapies, along with growing cell therapies development pipeline and encouraging clinical trial results, the cell therapies packaging market is anticipated to grow at a CAGR of 11.8% during the forecast period.
Enhanced Reliability on Outsourcing of Cell Therapy Packaging Operations
Given the need for costly and specialized equipment and the complexities related with the handling of cell-based therapy products, innovators in the healthcare industry are likely to involve contract service providers for their cell therapy packaging requirements. Further, the packaging of cell therapies requires significant investments in terms of time, expertise and resources which has led to an increased collaboration activity, in order to outsource the cell therapy packaging from an experienced partner. Outsourcing also allows the companies to overcome challenges associated with the stringent regulatory guidelines for cell therapy packaging products. Over the last few years, several service providers have also forged strategic alliances among themselves, in order to further expand existing capabilities and augment their respective service offerings.
Top Players in Cell Therapy Packaging Market
Examples of top market players that are engaged in offering cell therapy packaging products and services (which have also been profiled in this market report; in alphabetical order) Almac, Catalent Biologics, Cryoport Systems, Saint-Gobain, Thermo Fisher Scientific, West Pharmaceuticals and Yourway. This market report includes an easily searchable excel database of all the cell therapy packaging companies worldwide that offer products and services for packaging.
Recent Developments in Cell Therapy Packaging Market
Several recent developments have taken place in the field of cell therapy packaging to enhance safety and protection of the product, some of which have been outlined below. These developments, even if they took place post the release of the market report, substantiate the overall cell therapy packaging trends that the analyst has outlined in the analysis.
In October 2023, Cryoport entered into a partnership with Be The Match BioTherapies to expand the capabilities of IntegriCell™, which is a bioprocessing, cryopreservation and distribution solution for the cell therapy market.
In July 2023, Charles River Laboratories launched lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.
Cell Therapy Packaging Market Report Coverage
The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. Amongst other elements, the report includes:
- A preface providing an introduction to the full report, Cell Therapy Packaging Market, 2024-2035.
- An executive summary of the insights captured during the research. It offers a high-level view on the current state of cell therapy packaging market and its likely evolution in the mid to long term.
- A general overview of pharmaceutical filling and packaging, including information on types of pharmaceutical packaging. The chapter lays emphasis on cell therapy packaging, primary and secondary packaging of cell therapies. In addition, it discusses the key considerations and challenges associated with cell therapy packaging.
- An overview of the current market landscape of cell therapy packaging services providers, including a detailed analysis based on their year of establishment, company size, location of headquarters, type of services offered (packaging, distribution, storage, labeling, manufacturing, management solutions, drug return & destruction, serialization, analytical and other services), type of packaging (active and passive packaging), type of passive system offered (dry shippers and VIP insulations), packaging engineering design (primary and secondary packaging), phase change material used (dry ice and liquid nitrogen).
- A detailed assessment of the current market landscape of cell therapy packaging products, providing information on type of packaging container (bag, vial, shipping container and others), type of container fabrication material (plastic and others), raw materials for container fabrication (ethylene vinyl acetate (EVA), insulated panel, polypropylene, fluorinated ethylene propylene, USP class VI materials, polyethylene and others), type of cells packed (blood cells, hematopoietic cells, lymphocytes, stem cells, mesenchymal cells, cord blood cells, induced pluripotent cells and chondrocytes), storage conditions (ambient, refrigerated, freezing and cryogenic temperatures), and usability of container (single-use and multiple-use products). Further, the product providers have also been analyzed on the basis of parameters, such as their year of establishment, company size, location of headquarters and most active players (in terms of number of products).
- Elaborate profiles of the prominent players (shortlisted based on a proprietary criterion) engaged in offering cell therapy packaging products and services. Each profile features a brief overview of the company, details related to its service portfolio / product portfolio, recent developments and an informed future outlook.
- An in-depth competitiveness analysis of cell therapy packaging service providers based in different geographies, by taking into consideration the service strength of a company (based on its experience), packaging portfolio (package engineering design, type of packaging, type of packaging material and temperature ranges supported), service portfolio (type of additional services offered).
- An analysis of the various partnerships established between cell therapy packaging providers and cell therapy developers, during the period 2016-2021. It includes a brief description of various types of partnership models (namely service alliance, technology / platform integration agreement, merger and acquisition) adopted by stakeholders engaged in this domain. It is worth mentioning that the data captured during the research was analyzed based on several parameters, such as year of partnership, type of partnership, purpose of partnership, type of service offered, and geographical location of players involved in the partnership.
- A list of more than 250 cell therapy developers anticipated to partner with cell therapy packaging providers, which have been shortlisted on the basis of developer strength (based on company size), type of therapy and pipeline maturity (based on stage of development of drug candidate).
- A case study highlighting the companies that claim to have the required expertise and capabilities for development and manufacturing of cell therapies, along with the information on their year of establishment, company size, location of headquarters and location of manufacturing facility. In addition, the chapter presents analysis on type of cells manufactured, source of cells, scale of operation and manufacturing capabilities / services of the aforementioned companies.
- A detailed cell therapy packaging market forecast in order to estimate the current market size and future opportunity over the next 11 years. Based on multiple parameters, likely adoption of cell therapy packaging products and services and through secondary sources, the analyst has provided an informed estimate on the market size during the forecast period 2024-2035.
- Detailed projections of the current and future opportunity within the cell therapy packaging market across different type of therapies packed, such as T-cell therapies, dendritic cell vaccines, stem cell therapies, NK-cell therapies and other advanced therapy medicinal products.
- Detailed projections of the current and future opportunity within the cell therapy packaging market across different scales of operations, such as clinical and commercial.
- Detailed projections of the current and future cell therapy packaging market across different package engineering designs, such as primary packaging and secondary packaging.
- Detailed projections of the current and future opportunity within the cell therapy packaging market across key geographical regions, such as North America, Europe, Asia-Pacific and Rest of the World.
One of the key objectives of this cell therapy packaging report was to estimate the current market size, opportunity and the future growth potential for cell therapy packaging providers, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, the analyst has provided informed estimates on the likely evolution of the market for the forecast period, 2024-2035.
The market report also features the likely distribution of the current and forecasted opportunity within the cell therapy packaging market across various segments, such as type of therapy packed (T-cell therapies, dendritic cell vaccines, stem cell therapies, NK-cell therapies and other advanced therapy medicinal products), scale of operations (clinical and commercial), package engineering design (primary and secondary) and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties associated with some of the key parameters and to add robustness to the model, the analyst has provided three cell therapy packaging market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market growth.
The opinions and insights presented in this market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
- Founder and Owner, Small Company, Germany
- Chief Financial Officer, Small Company, Germany
- Chief Business Officer, Small Company, US
- Senior Director of Scientific Affairs and Technical Marketing, Small Company, US
- Vice President, Peptides, Large Company, Ireland
- Senior Manager, Peptide Business Project Leader, Large Company, Japan
Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Key Benefits of Buying this Report
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the Cell Therapy Packaging Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3P Biopharmaceuticals
- A2 Biotherapeutics
- A4P
- AbClon
- Abeona Therapeutics
- AccuResearch Korea
- Achilles Therapeutics
- Adaptimmune Therapeutics
- Adicet Bio
- ADVATIS
- Advent Biologics
- Aegle Therapeutics
- Aeon Therapeutics
- AffyImmune Therapeutics
- AGC Biologics
- AgenTus Therapeutics
- Akron Biologics
- Alitalia
- Allele Biotechnology and Pharmaceuticals
- AlLife Medicine
- Allogene Therapeutics
- Almac
- Almog
- Altaco XXI
- Angiocrine Bioscience
- Anterogen
- apceth Biopharma (acquired by Hitachi Chemical)
- Arbele
- Arcellx
- Aseptic Technologies
- Aspire Health Science
- Astellas Pharma
- Asutrianova
- Atara Biotherapeutics
- Athersys
- Atlantis Bioscience
- Aurora Biopharma
- Autolus Therapeutics
- Axis Biotec
- Azenta LifeSciences
- Azidus
- Baylx
- Beijing Biohealthcare Biotechnology
- Beijing Doing Biomedical
- Beijing Sanwater Biological Technology
- Bellicum Pharmaceuticals
- BHI Therapeutic Sciences
- Bio Elpida
- Biocair
- BioCardia
- Bioceltech Therapeutics
- BioCentriq
- BioInno Bioscience
- Bioinova
- BioLife Solutions
- BioNTech Manufacturing
- Biopharma Dynamics
- Bioquark
- BioRestorative Therapies
- Biotech & Pharma Logistics
- Biowy
- bluebird bio
- BlueRock Therapeutics (acquired by Bayer)
- Bone Therapeutics
- BrainStorm Cell Therapeutics
- Bristol Myers Squibb
- Brooks Life Sciences
- Bukwang Pharmaceutical
- Caladrius Biosciences
- Capricor Therapeutics
- CAR-T (Shanghai) Biotechnology
- Carina Biotech
- CARsgen Therapeutics
- Cartesian Therapeutics
- Cartherics
- Catalent Biologics
- Celgene
- Celixir
- Cell and Gene Therapy Catapult
- Cell Medica
- Cell Therapies
- Cell-Easy
- Cellectis
- Cellerant Therapeutics
- Cellex
- Cellin Technologies
- CellMP
- CellProtect Nordic Pharmaceuticals
- CellProthera
- Cellular Biomedicine
- Celonic
- Celularity
- Celyad Oncology
- CENTOGENE
- Cesca Therapeutics
- CHA Biotech
- Chart Industries
- Charter Medical
- Chiesi
- China Immunotech (Beijing) Biotechnology
- China Regenerative Medicine
- Chongqing Precision Biotech
- Clean Cells
- Co.don
- Cognate BioServices (acquired by Charles River Laboratories)
- CoImmune
- Cold Chain Technologies
- ColdStash
- Cook MyoSite
- Cook Pharmica
- Core Cryolab
- CORESTEM
- CRISPR Therapeutics
- Critical Transport Solutions Australia
- Cryo-Cell
- CryoGene
- CRYOPDP
- CRYOPDP (acquired by Cryoport)
- Cryoport
- CSafe Global
- Cynata Therapeutics
- Cytiva
- CytoMed Therapeutics
- Cytopeutics
- Cytovac
- Dendreon Pharmaceuticals
- DiscGenics
- EHL Bio
- ElevateBio
- Eli Lilly
- EpiBone
- EUMA Biotech
- Eutilex
- Ever Supreme Bio Technology
- EVERSANA
- Fate Therapeutics
- Ferrer Internacional
- Fibrocell Science
- Formula Pharmaceuticals
- Fortress Biotech
- Fosun Kite Biotechnology
- Froceth
- FUJIFILM Irvine Scientific
- Gamida Cell
- GC Cell
- GC Pharma
- GE Healthcare
- GenCure
- Genenta Science
- GenIbet Biopharmaceuticals
- Genus Oncology
- GigaGen
- GlaxoSmithKline
- Global Cell Med
- Glycostem Therapeutics
- Gracell Biotechnologies
- Greiner Bio-One
- Gwo xi Stem Cell
- Hebei Newtherapy BIo-Pharma technology
- Hebei Senlang Biotechnology
- Helix BioPharma
- HemaCare
- Hemostemix
- Histocell
- Hitachi Chemical
- Holostem Terapie Avanzate
- Hope Biosciences
- Horizon Discovery
- Hrain Biotechnology
- iCell Gene Therapeutics
- Icell Kealex Therapeutics
- ICS
- ilaya
- Immatics
- Immetacyte
- Immune Therapeutics
- Immuneel Therapeutics
- Immunocore
- Immunovative Therapies
- IncoCell Tianjin
- INNOFORCE
- Innovative Cellular Therapeutics
- Instant Systems
- Instil Bio
- Intellia Therapeutics
- Intelsius
- International Stem Cell
- Invectys
- Iovance Biotherapeutics
- Ixaka
- Janssen
- Japan Regenerative Medicine
- Japan Tissue Engineering
- jCyte
- Jiuzhitang Maker Cell Technology
- Juno Therapeutics
- Juventas Cell Therapy
- JW CreaGene
- JW Therapeutics
- K-Stem Cell
- Kadimastem
- KAEDI
- Kangstem Biotech
- KBI Biopharma
- Kiadis Pharma
- Kite Pharma
- KLSMC Stem Cells
- KSQ Therapeutics
- Kymanox
- Lai
- LATAM Cargo
- Legend Biotech
- Leucid Bio
- LifeCell
- Lineage Cell Therapeutics
- Lion TCR
- Living Pharma
- Longeveron
- Lonza
- Lykan Bioscience
- Macopharma
- Magellan Biologicals
- Magenta Therapeutics
- Marken
- Marker Therapeutics
- McKesson
- Med Cell Bahamas
- Medeor Therapeutics
- Medigene
- MEDINET
- MEDIPOST
- Medisix Therapeutics
- Melbourne Stem Cell Centre
- Mercury
- Meridigen Biotech
- Mesoblast
- Miltenyi Biomedicine
- Minaris Regenerative Medicine
- Minerva Biotechnologies
- MingJu Therapeutics
- Minovia Therapeutics
- MNX Global Logistics
- MolMed
- Multimmune
- Mustang Bio
- MVE Biological Solutions
- Müller + Müller (acquired by DWK Life Sciences)
- Nanjing Bioheng Biotech
- NanoCool
- NantKwest
- Nature Cell
- NeuroGeneration
- NextCell Pharma
- Nikon CeLL Innovation
- Nipro Europe Group Companies
- Nkarta
- NKMax America
- Nohla Therapeutics
- Noile-Immune Biotech
- Noray Biosciences Group
- Novadip Biosciences
- Novartis
- Novex Innovations
- NuVasive
- Obsidian Therapeutics
- Ology Bioservices
- Orca Bio
- Orchard Therapeutics
- OrganaBio
- OriGen Biomedical
- Orthofix
- Osiris Therapeutics
- Oxford Biomedica
- PACT Pharma
- Patheon
- Pelican BioThermal
- PeproMene Bio
- Personalized Stem Cells
- PersonGen BioTherapeutics
- PharmaBio
- Pharmicell
- Phio Pharmaceuticals
- Pluristem Therapeutics
- Plus Therapeutics
- Poseida Therapeutics
- Precigen
- Precision BioSciences
- Promethera Biosciences
- Protheragen
- Provia Laboratories
- Q Therapeutics
- Quick
- QuickSTAT
- R3 Stem Cell
- Regeneus
- Regenexx
- Reliance Life Sciences
- ReNeuron
- Riordan Technologies
- Riyadh Pharma
- ROHTO Pharmaceutical
- Roslin Cell Therapies
- Roylance Pharma
- RTI Surgical
- Rubius Therapeutics
- S-RACMO
- S.Biomedics
- SABZ Biomedicals
- Saint-Gobain
- Salvat
- SanBio
- Sangamo Therapeutics
- Savillex
- SAVSU Technologies (subsidiary of BioLife Solutions)
- SCHOTT
- Sclnow Biotechnology
- SCM Lifescience
- Seattle Genetics
- Seneca Biopharma
- Sensei Biotherapeutics
- Sentien Biotechnologies
- Sequel Logistics
- Servier
- SGD Pharma
- Shandong Qilu Stem Cells Engineering
- Shanghai Biomed-Union Biotechnology
- Shanghai GeneChem
- Shanghai iCELL Biotechnology
- Shanghai Longyao Biotechnology
- Shenzhen Binde Biotechnology
- Shenzhen Hornetcorn Biotechnology
- Single Use Support
- Sinobioway Cell Therapy
- SMT Bio
- Sorrento Therapeutics
- SOTIO
- Stem Cell Medicine
- Stem Med
- STEMCELL Technologies
- Stemedica Cell Technologies
- Steminent Biotherapeutics
- Stemmatters
- Stempeutics Research
- Stryker
- Sumitomo Dainippon Pharma
- Suzuken
- Swiss Medica XXI Century
- Swiss WorldCargo
- Tactiva Therapeutics
- Taiwan Bio Therapeutics
- Takara Bio
- Takeda Pharmaceutical
- Talaris Therapeutics
- Targazyme
- TC BioPharm
- TCR2 Therapeutics
- Technoflex
- Teneobio
- Terumo
- Tessa Therapeutics
- The Emmes Company
- Thermo Fisher Scientific
- Tianhe Stem Cell Biotechnologies
- Tianjin Ever Union Biotechnology
- Tianjin Mycure Medical Technology
- Tianjin Weikai Biological Engineering
- TICEBA
- TiGenix
- TILT Biotherapeutics
- time:matters
- Timmune Biotech
- Tissue Solutions
- Tmunity Therapeutics
- TrakCel
- TreeFrog Therapeutics
- Tscan Therapeutics
- TVAX Biomedical
- U.S. Stem Cell
- Ucardi Biomedical Technology
- United Cargo
- United Parcel Services (UPS)
- United Therapeutics
- University College of London
- Unum Therapeutics
- UWELL Biopharma
- va-Q-tec
- VcanBio Center for Translational Biotechnology
- Vericel
- VetStem Biopharma
- ViaCyte
- Vineti
- Viscofan BioEngineering
- Vitalant
- Waisman Biomanufacturing
- Wellington Zhaotai Therapies
- West
- West Biotherapy
- West Pharmaceutical Services
- World Courier
- Wugen
- WuXi Advanced Therapies
- Xiangxue Life Sciences
- Yourway
- Zelluna Immunotherapy
- Zumutor Biologics
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 204 |
Published | May 2024 |
Forecast Period | 2024 - 2035 |
Estimated Market Value ( USD | $ 361 Million |
Forecasted Market Value ( USD | $ 1225 Million |
Compound Annual Growth Rate | 11.8% |
Regions Covered | Global |